Developer docs
API playgroundTry for free, no card

Search company profiles

Rapamycin Longevity Lab

Full company profile

uuid00smjto

Namestring
Rapamycin Longevity Lab
Legal namestring
Venture Plant AB
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Rapamycin Longevity Lab is a Gothenburg, Sweden-based research coordination entity founded in 2024 by Krister Kauppi and operated as part of Venture Plant AB, a Swedish private limited company. The organization has 1-10 employees and does not perform laboratory work itself; instead, it coordinates and funds high-throughput longevity screening of mTOR inhibitors through a strategic partnership with Ora Biomedical, whose WormBot-AI platform combines robotics and AI to perform massively high-throughput longevity analysis in Caenorhabditis elegans (roundworms). The lab's core initiative is a coordinated research project to screen 601 mTOR inhibitors for healthy lifespan effects in C. elegans, split into two subprojects with budgets of $50,000 (Subproject 1, fully funded) and $60,000 (Subproject 2, in active fundraising), with all resulting data released publicly through Ora Biomedical's database within three months of project funding.

The lab's broader product surface includes the Longevity Intervention Database (LID), a public database cataloging intervention effects across species and strains; the Longevity Wormbot Program (LOOP), an annual recurring screening cadence; and the Rapamycin Longevity Series podcast featuring interviews with longevity researchers such as Matt Kaeberlein, Joan Mannick, Brian Kennedy, and Mikhail Blagosklonny. Marketing and distribution are community-driven, leveraging YouTube live streams, the podcast, social media, and media partnerships with Lifespan.io and Rapamycin.news.

The business model is community-driven philanthropy rather than commercial revenue capture. The lab does not charge for membership or take commissions on funds raised. Instead, it recruits community members (targeting 3,000 for Project 2) and accepts tiered sponsorships (Gold $10,000, Silver $5,000, Bronze $1,000) that flow directly to Ora Biomedical for screening work. Customers are effectively longevity enthusiasts, mTOR inhibitor community members, and longevity researchers who fund and consume the lab's publicly available outputs. The organization is certified as a Vitalist Organization by Vitalism.io and operates without disclosed commercial revenue.

Short descriptiontext

Gothenburg-based research coordinator founded by Krister Kauppi in 2024 that raises sponsorship funds and partners with Ora Biomedical to coordinate high-throughput screening of 601 mTOR inhibitors for longevity in C. elegans, operating a public longevity intervention database and educational podcast.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersGothenburg, Sweden
HQ citystring
Gothenburg
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
longevity research, mTOR inhibitor screening, research coordination, biomedical research funding, healthspan science
Industry1 code
PRIMARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
Product category
Longevity Research Coordination
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Research Project Funding/Sponsorships
TypeAffiliate Referral
Description

Funding is raised through sponsorship tiers (Gold $10k, Silver $5k, Bronze $1k) for specific mTOR inhibitor screening projects. All funds go directly to Ora Biomedical for screening work. Rapamycin Longevity Lab coordinates and leads projects without taking commission.

rapamycinlongevitylab.com
2Free Membership Program
TypeFreemium
Description

Free membership program providing exclusive project updates and information. Revenue not directly generated; serves as community-building mechanism for future fundraising.

rapamycinlongevitylab.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Marketing or Sales, Operations
GTM typeB2C
B2C
Offering typeServices
Services
Brand1 of 2 records shown
1Longevity Intervention Database (LID)
Description

A comprehensive database of longevity interventions featuring data on lifespan effects across multiple species including Caenorhabditis elegans, Drosophila, mice, and rats.

rapamycinlongevitylab.com
+1 more record
Core offering1 text field

Rapamycin Longevity Lab coordinates community-funded longevity research projects, most prominently partnering with Ora Biomedical to screen 601 mTOR inhibitors for lifespan effects in the roundworm Caenorhabditis elegans using the WormBot-AI platform. The lab also maintains a publicly accessible Longevity Intervention Database (LID) and produces the Rapamycin Longevity Series podcast for educational outreach.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 601 mTOR inhibitors screened for lifespan effects in C. elegans
+2 more records
Product overview1 text field

Rapamycin Longevity Lab operates as a research coordination organization focused on accelerating longevity science around Rapamycin and mTOR inhibitors. The core offering consists of the mTOR Inhibitor Screening Project, which partners with Ora Biomedical to screen 601 mTOR inhibitors using the WormBot-AI platform. This is supported by the Longevity Intervention Database (LID), a public database aggregating lifespan data across species and interventions. The organization also conducts the annual Longevity Wormbot Program (LOOP) for ongoing candidate testing, and produces the Rapamycin Longevity Series Podcast for educational outreach.

Product and service4 records
1mTOR Inhibitor Screening Project
CategoryResearch Coordination Service
Description

Research initiative coordinated with Ora Biomedical to conduct comprehensive lifespan analysis of 601 mTOR inhibitors in the roundworm Caenorhabditis elegans, using the WormBot-AI platform for high-throughput screening. Sponsored by individual contributors and longevity-focused companies.

2Longevity Intervention Database (LID)
CategoryDatabase / Research Resource
Description

Publicly accessible online database cataloging longevity interventions and their effects on median and maximum lifespan across different species, strains, and genders, with filtering capabilities.

3Longevity Wormbot Program (LOOP)
CategoryResearch Program
Description

Annual screening program that continues the partnership with Ora Biomedical to test selected mTOR inhibitors at multiple doses in roundworms, identifying optimal candidates for further longevity research.

4Rapamycin Longevity Series Podcast
CategoryEducational Content
Description

Podcast series featuring expert interviews with scientists and physicians (including Joan Mannick, Brian Kennedy, Mikhail Blagosklonny, Matt Kaeberlein, and others) discussing Rapamycin, mTOR inhibition, and longevity research topics.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeTechnology or Integration
Description

Strategic partnership to coordinate lifespan analysis of 601 mTOR inhibitors using Ora Biomedical's WormBot-AI technology. Matt Kaeberlein, co-founder of Ora Biomedical and world-leading Rapamycin researcher, provides scientific expertise. The WormBot platform combines robotics and AI for massively high-throughput longevity screening in roundworms. Rapamycin Longevity Lab coordinates and leads the research project while all screening work is conducted by Ora Biomedical. All resulting data will be publicly available.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Media supporter for the mTOR inhibitor screening project. Provides promotional support and visibility within the longevity community.

3Rapamycin.news
Strategic tierMinorTypeGTM or Marketing Partner
Description

Media supporter providing coverage and visibility for longevity research projects.

rapamycinlongevitylab.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Telehealth provider of rapamycin and other longevity interventions, listed as a sponsor of Rapamycin Longevity Lab. Comparable focus on translating mTOR science into accessible longevity offerings for consumers.

TypeEmerging player
Description

Sam Altman-backed longevity biotech using epigenetic reprogramming. Operates in adjacent longevity biology space with overlapping founder/funder networks in the longevity community.

TypeDirect peer
Description

Core technology partner running WormBot-AI screening. Both organizations are focused on mTOR inhibitor longevity research in C. elegans and share scientific leadership via Matt Kaeberlein, making Ora Biomedical the closest functional peer.

TypeBroad incumbent
Description

AI-driven drug discovery company with active aging and longevity pipeline. Comparable in combining AI and high-throughput biology to identify geroprotective compounds, including those targeting mTOR pathways.

TypeBroad incumbent
Description

Alphabet-backed longevity research company pursuing aging biology broadly. Comparable in mission to extend healthy human lifespan and has the resources to run large-scale compound screening programs that could overlap with the lab's mTOR focus.

TypeEmerging player
Description

FDA-conditional-approved developer of a longevity drug for dogs targeting mTOR. Operates in the same mTOR-inhibitor longevity regulatory and scientific frontier, providing a downstream translational reference point for the lab's C. elegans work.

TypeDirect peer
Description

Longevity research media and crowdfunding platform that has partnered with Rapamycin Longevity Lab. Both operate community-driven funding models for longevity science and share overlapping sponsor bases in the rapamycin/mTOR space.

TypeBroad incumbent
Description

Well-capitalized longevity biotech pursuing cellular rejuvenation across multiple biological pathways including mTOR. Operates in the same longevity biology space with vastly greater resources, making it a strategic competitor for talent and attention.

TypeDirect peer
Description

Sponsor of the lab's Subproject 1 and a community-driven open-science longevity research organization. Comparable mission of accelerating longevity research through distributed funding and open data.

TypeEmerging player
Description

Longevity-focused consumer health company sponsoring the lab's first subproject. Both target the same health-conscious longevity audience and benefit from advances in mTOR-inhibitor longevity research.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Rapamycin Longevity Lab

Longevity Research Coordinationrapamycinlongevitylab.com

Gothenburg-based research coordinator founded by Krister Kauppi in 2024 that raises sponsorship funds and partners with Ora Biomedical to coordinate high-throughput screening of 601 mTOR inhibitors for longevity in C. elegans, operating a public longevity intervention database and educational podcast.

What Rapamycin Longevity Lab does

Rapamycin Longevity Lab is a Gothenburg, Sweden-based research coordination entity founded in 2024 by Krister Kauppi and operated as part of Venture Plant AB, a Swedish private limited company. The organization has 1-10 employees and does not perform laboratory work itself; instead, it coordinates and funds high-throughput longevity screening of mTOR inhibitors through a strategic partnership with Ora Biomedical, whose WormBot-AI platform combines robotics and AI to perform massively high-throughput longevity analysis in Caenorhabditis elegans (roundworms). The lab's core initiative is a coordinated research project to screen 601 mTOR inhibitors for healthy lifespan effects in C. elegans, split into two subprojects with budgets of $50,000 (Subproject 1, fully funded) and $60,000 (Subproject 2, in active fundraising), with all resulting data released publicly through Ora Biomedical's database within three months of project funding.

The lab's broader product surface includes the Longevity Intervention Database (LID), a public database cataloging intervention effects across species and strains; the Longevity Wormbot Program (LOOP), an annual recurring screening cadence; and the Rapamycin Longevity Series podcast featuring interviews with longevity researchers such as Matt Kaeberlein, Joan Mannick, Brian Kennedy, and Mikhail Blagosklonny. Marketing and distribution are community-driven, leveraging YouTube live streams, the podcast, social media, and media partnerships with Lifespan.io and Rapamycin.news.

The business model is community-driven philanthropy rather than commercial revenue capture. The lab does not charge for membership or take commissions on funds raised. Instead, it recruits community members (targeting 3,000 for Project 2) and accepts tiered sponsorships (Gold $10,000, Silver $5,000, Bronze $1,000) that flow directly to Ora Biomedical for screening work. Customers are effectively longevity enthusiasts, mTOR inhibitor community members, and longevity researchers who fund and consume the lab's publicly available outputs. The organization is certified as a Vitalist Organization by Vitalism.io and operates without disclosed commercial revenue.

Rapamycin Longevity Lab firmographics

Firmographics
Name
Rapamycin Longevity Lab
Legal name
Venture Plant AB
Website
https://rapamycinlongevitylab.com
Company type
Private
Operating status
Operating
Headcount range
1–10 employees
Short description
Gothenburg-based research coordinator founded by Krister Kauppi in 2024 that raises sponsorship funds and partners with Ora Biomedical to coordinate high-throughput screening of 601 mTOR inhibitors for longevity in C. elegans, operating a public longevity intervention database and educational podcast.
Ownership category
akta.pro rank

Rapamycin Longevity Lab industry classification

Industry
Product category
Longevity Research Coordination
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
akta.pro industry
PRIMARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Longevity research
  • MTOR inhibitor screening
  • Research coordination
  • Biomedical research funding
  • Healthspan science

Where Rapamycin Longevity Lab is headquartered

Location

Headquarters

HQ city
Gothenburg
HQ country
Sweden
HQ region
Europe

Offices1 record

Markets served

Rapamycin Longevity Lab business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Technology or R&D, Marketing or Sales, Operations

Revenue model

  1. Research Project Funding/Sponsorships: Funding is raised through sponsorship tiers (Gold $10k, Silver $5k, Bronze $1k) for specific mTOR inhibitor screening projects. All funds go directly to Ora Biomedical for screening work. Rapamycin Longevity Lab coordinates and leads projects without taking commission.
  2. Free Membership Program: Free membership program providing exclusive project updates and information. Revenue not directly generated; serves as community-building mechanism for future fundraising.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Rapamycin Longevity Lab product offering

Product offering

Core offering

Rapamycin Longevity Lab coordinates community-funded longevity research projects, most prominently partnering with Ora Biomedical to screen 601 mTOR inhibitors for lifespan effects in the roundworm Caenorhabditis elegans using the WormBot-AI platform. The lab also maintains a publicly accessible Longevity Intervention Database (LID) and produces the Rapamycin Longevity Series podcast for educational outreach.

Product overview

Rapamycin Longevity Lab operates as a research coordination organization focused on accelerating longevity science around Rapamycin and mTOR inhibitors. The core offering consists of the mTOR Inhibitor Screening Project, which partners with Ora Biomedical to screen 601 mTOR inhibitors using the WormBot-AI platform. This is supported by the Longevity Intervention Database (LID), a public database aggregating lifespan data across species and interventions. The organization also conducts the annual Longevity Wormbot Program (LOOP) for ongoing candidate testing, and produces the Rapamycin Longevity Series Podcast for educational outreach.

Differentiator

Problem solved

Functional benefit

Brands

  • Longevity Intervention Database (LID): A comprehensive database of longevity interventions featuring data on lifespan effects across multiple species including Caenorhabditis elegans, Drosophila, mice, and rats.
  • Rapamycin Longevity Series

Products and services

  • mTOR Inhibitor Screening Project Research initiative coordinated with Ora Biomedical to conduct comprehensive lifespan analysis of 601 mTOR inhibitors in the roundworm Caenorhabditis elegans, using the WormBot-AI platform for high-throughput screening. Sponsored by individual contributors and longevity-focused companies.
  • Longevity Intervention Database (LID) Publicly accessible online database cataloging longevity interventions and their effects on median and maximum lifespan across different species, strains, and genders, with filtering capabilities.
  • Longevity Wormbot Program (LOOP) Annual screening program that continues the partnership with Ora Biomedical to test selected mTOR inhibitors at multiple doses in roundworms, identifying optimal candidates for further longevity research.
  • Rapamycin Longevity Series Podcast Podcast series featuring expert interviews with scientists and physicians (including Joan Mannick, Brian Kennedy, Mikhail Blagosklonny, Matt Kaeberlein, and others) discussing Rapamycin, mTOR inhibition, and longevity research topics.

Quantifiable outcome

  • 601 mTOR inhibitors screened for lifespan effects in C. elegans
  • +2 more outcomes

Companies that use Rapamycin Longevity Lab

Customer profile

Segments3 records

Ideal customer profiles3 records

Rapamycin Longevity Lab technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Rapamycin Longevity Lab partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Ora BiomedicalcoreTechnology or IntegrationStrategic partnership to coordinate lifespan analysis of 601 mTOR inhibitors using Ora Biomedical's WormBot-AI technology. Matt Kaeberlein, co-founder of Ora Biomedical and world-leading Rapamycin researcher, provides scientific expertise. The WormBot platform combines robotics and AI for massively high-throughput longevity screening in roundworms. Rapamycin Longevity Lab coordinates and leads the research project while all screening work is conducted by Ora Biomedical. All resulting data will be publicly available.
  • Lifespan.iominorGTM or Marketing PartnerMedia supporter for the mTOR inhibitor screening project. Provides promotional support and visibility within the longevity community.
  • Rapamycin.newsminorGTM or Marketing PartnerMedia supporter providing coverage and visibility for longevity research projects.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Rapamycin Longevity Lab competitors and assessment

Company assessment

Emerging players

  • AgelessRx: Telehealth provider of rapamycin and other longevity interventions, listed as a sponsor of Rapamycin Longevity Lab. Comparable focus on translating mTOR science into accessible longevity offerings for consumers.
  • NewLimit: Sam Altman-backed longevity biotech using epigenetic reprogramming. Operates in adjacent longevity biology space with overlapping founder/funder networks in the longevity community.
  • Loyal for Dogs: FDA-conditional-approved developer of a longevity drug for dogs targeting mTOR. Operates in the same mTOR-inhibitor longevity regulatory and scientific frontier, providing a downstream translational reference point for the lab's C. elegans work.
  • Healthspan: Longevity-focused consumer health company sponsoring the lab's first subproject. Both target the same health-conscious longevity audience and benefit from advances in mTOR-inhibitor longevity research.

Direct peers

  • Ora Biomedical: Core technology partner running WormBot-AI screening. Both organizations are focused on mTOR inhibitor longevity research in C. elegans and share scientific leadership via Matt Kaeberlein, making Ora Biomedical the closest functional peer.
  • Lifespan.io: Longevity research media and crowdfunding platform that has partnered with Rapamycin Longevity Lab. Both operate community-driven funding models for longevity science and share overlapping sponsor bases in the rapamycin/mTOR space.
  • OpenCures: Sponsor of the lab's Subproject 1 and a community-driven open-science longevity research organization. Comparable mission of accelerating longevity research through distributed funding and open data.

Broad incumbents

  • Insilico Medicine: AI-driven drug discovery company with active aging and longevity pipeline. Comparable in combining AI and high-throughput biology to identify geroprotective compounds, including those targeting mTOR pathways.
  • Calico Life Sciences: Alphabet-backed longevity research company pursuing aging biology broadly. Comparable in mission to extend healthy human lifespan and has the resources to run large-scale compound screening programs that could overlap with the lab's mTOR focus.
  • Altos Labs: Well-capitalized longevity biotech pursuing cellular rejuvenation across multiple biological pathways including mTOR. Operates in the same longevity biology space with vastly greater resources, making it a strategic competitor for talent and attention.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Rapamycin Longevity Lab social profiles

Digital presence

Rapamycin Longevity Lab financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Rapamycin Longevity Lab leadership team

Management profile

Number of profiles

Profiles1 record

Rapamycin Longevity Lab funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Rapamycin Longevity Lab M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rapamycin Longevity Lab

What does Rapamycin Longevity Lab do?

Rapamycin Longevity Lab coordinates community-funded longevity research projects, most prominently partnering with Ora Biomedical to screen 601 mTOR inhibitors for lifespan effects in the roundworm Caenorhabditis elegans using the WormBot-AI platform. The lab also maintains a publicly accessible Longevity Intervention Database (LID) and produces the Rapamycin Longevity Series podcast for educational outreach.

Is Rapamycin Longevity Lab a public or private company?

Rapamycin Longevity Lab is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Rapamycin Longevity Lab founded?

Rapamycin Longevity Lab was founded in -1. It employs 1 to 10 people.

Where is Rapamycin Longevity Lab based?

Rapamycin Longevity Lab is headquartered in Gothenburg, Sweden, in the Europe region.

How does Rapamycin Longevity Lab make money?

Two revenue lines are on record. Research Project Funding/Sponsorships are the primary driver. The others are free Membership Program.

Who are Rapamycin Longevity Lab's main competitors?

Emerging players on record are AgelessRx, NewLimit, Loyal for Dogs and Healthspan. Direct peers are Ora Biomedical, Lifespan.io and OpenCures. Broad incumbents are Insilico Medicine, Calico Life Sciences and Altos Labs.

Does Rapamycin Longevity Lab have an API?

No public API is recorded for Rapamycin Longevity Lab.

What industry is Rapamycin Longevity Lab in?

Rapamycin Longevity Lab's product category is Longevity Research Coordination. Its primary akta.pro industry code is HLAGAEAD, Genomics & Molecular Diagnostics (Trial Support). Its NAICS code is 541714.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales